It’s golden ticket time for the annual @uromigos meeting in Nashville(Sept 27/28). Sessions on novel and preoperative therapies, biomarkers, new trial designs and the Uromigos cup will occur. The best novel ‘UROMIGOS’ design photo will win a golden ticket . Below is our attempt.

Our Dr. Pavlos Msaouel specializes in treating renal medullary carcinoma. Here, he explains the link between sickle cell trait, high-intensity exercise and this rare kidney cancer: bit.ly/3WVCsP8 Pavlos Msaouel #KidneyCancer #EndCancer

A comprehensive cancer center has exceptional specialty care for kidney cancer treatment. Discover more about building your care team and find additional resources, including an interactive map of comprehensive cancer centers, at kidneycan.org #AcceleratingCures

💫🌟Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab 🌟💫 Moshe Ornstein MD, Laeth George, MD, Allison Martin, MD MPH Arnab Basu, @katyn_beckermann, arianna amanda Binti Ahmad Nizam, Christopher Wee, MD, Tim Gilligan,

Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment, and follow-up! ESMO - Eur. Oncology Tom Powles Laurence Albiges Viktor Grünwald Ravindran Kanesvaran Rana McKay, MD, FASCO Giuseppe Procopio silke gillessen Cris Jeremy Teoh Guillermo de Velasco OncoAlert KidneyCAN Kidney Cancer

The KCRP Idea Development Award is now open for applications! If you have an innovative idea or a high-impact approach to advancing #KidneyCancer research, this is your chance to make a difference. Apply now! cdmrp.health.mil/funding/kcrp #AcceleratingCures

Our virtual Advocacy Days are fast approaching, and we need passionate advocates to join us. Together, we can secure the funding needed for #KidneyCancer research. Help us make a difference—sign up today! 🔗 bit.ly/Fall24Advocacy #AcceleratingCures

We congratulate Qing Zhang, PhD, one of the 2024 recipients of the AACR-KidneyCAN Kidney Cancer Innovation and Discovery Grants. We look forward to his insights on potential therapeutic options that can reverse drug resistance to HIF-2α inhibitors in kidney cancer. KidneyCAN

AACR KidneyCAN Thank you very much for your generous supports for our exploratory research on targeting HIF2a resistant in kidney cancer!

LITESPARK-013 study(phase-2 randomized): ⚡️Belzutifan 120 mg daily offers similar efficacy as the 200 mg dose in advanced clear cell RCC patients post anti–PD-(L)1 therapy. ⚡️With comparable ORR, PFS, and OS, 120 mg emerges as the preferred dose. ‼️More dose modifications and

Dr. Sabina Signoretti Brigham and Women's Hospital presented on Sarcomatoid RCC at #KCRS24. While it’s a challenging diagnosis with limited treatment options, recent immunotherapy trials offer new hope for patients. Check out more presentations at kcrs.kidneycan.org #AcceleratingCures

Just in Annals of Oncology 👉on the heels of the recent approval of belzutifan in mRCC #kidneycancer , herein we show in a ph2 randomized trial👉more belzutifan (200 mg vs 120 mg QD) was not better👇Link: tinyurl.com/nrsxp8s4 UroToday.com OncoAlert KidneyCAN Huntsman Cancer Institute

Thanks to the relentless efforts of our grassroots army, the #KidneyCancer Research Program is making real strides in saving lives right now. Help us continue doing so by advocating for more funding—your voice makes a difference! 🔗 bit.ly/Fall24Advocacy #AcceleratingCures

The internet can be overwhelming, which is why we’ve curated a list of trustworthy sites to help you understand your kidney cancer diagnosis and treatment options. Discover more at our Patient Resource Center: kidneycan.org #AcceleratingCures

When you invest just a few hours in our Virtual Advocacy Days, you could help secure millions in research funding. Your voice matters! Join us in making a difference for #KidneyCancer patients everywhere. 🔗 Sign up now: bit.ly/Fall24Advocacy #AcceleratingCures

The Clinical Trial Award is your opportunity to push the boundaries of kidney cancer research. This award supports innovative clinical trials that could have a significant impact on treatment and patient outcomes. 🔗 Learn more: cdmrp.health.mil/funding/kcrp #AcceleratingCures

The Vanderbilt University Ingram Cancer Center Genitourinary team is expanding. We are seeking a GU medical oncology clinical investigator to join our innovative team. Please message me or Brian Rini, MD to inquire further. We will also be at #ESMO24

Out today in TIME — a review of recent advances in #KidneyCancer treatment highlighting the incredible work of Toni Choueiri, MD Dana-Farber Lank Center for Genitourinary Oncology Brian Rini, MD Vanderbilt Hem / Onc william huang nyulmc Katie Spina (she/her) Columbia RadOnc George R Schade Fred Hutchinson Cancer Center and many others! It takes a village to

As a patient diagnosed within the last year, it’s so so so important for folks to realize many numbers and stats are backwards looking when it comes to treatments, etc. while there is a long way to go, there have been awesome strides in kidney cancer treatment/research. Thankful

KidneyCAN TIME Toni Choueiri, MD Dana-Farber Lank Center for Genitourinary Oncology Brian Rini, MD Vanderbilt Hem / Onc william huang nyulmc Katie Spina (she/her) Columbia RadOnc George R Schade Fred Hutchinson Cancer Center Exciting to see the kidney cancer community coming together to accelerate cures! The progress made in the past two decades is a testament to the power of collaboration and innovation.